• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

    2/13/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VOR alert in real time by email
    • Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials
    • Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options

    CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials. The data, which was presented at the TANDEM Meetings of ASTCT and CIBMTR, demonstrated the need to improve the process and experience of patients considering and enrolling in CGT trials.

    "This original research emphasizes the unique challenges involved in offering and educating patients about cell and gene therapy trials and also highlights physician interest in the promise these novel therapies may provide to patients," said Dr. Eyal Attar, Vor Bio's Chief Medical Officer. "These learnings will help us improve the patient experience in our own trials and provide a roadmap for everyone involved in the clinical trial enrollment process as we strive to educate patients about these novel, yet often complicated, therapies."

    Despite the growing number of CGT trials, their complexity, logistical challenges including treatment duration and caregiver burden, and the significant resources they require represent important barriers that delay enrollment and limit patient access. The study was designed to investigate these key barriers by evaluating challenges facing patients, clinical staff, and institutions. The study conducted and analyzed surveys and interviews with 30 physicians, study coordinators, research nurses, and other clinicians who participate in the patient consent process, as well as patient advocacy partners.

    Key findings from the data:

    • Educating patients and enrolling them in CGT trials requires more time compared to non-CGT trials due to their complexity and patients' need for additional reassurance or emotional support.
    • Despite the extra time required to educate patients, this did not prevent any survey participants from offering these trials to patients, underscoring the transformative potential of these treatments.
    • Study respondents reported that patients share many concerns about CGT trials, including the fear of unknown risks of gene editing and caregiver requirements.

    The results reveal significant opportunities for institutions and trial sponsors to improve the patient experience, streamline the process, and enroll more patients in CGT trials. Clinical trial sponsors can address the complexity of cell and gene therapies and help patients better understand these options by providing more comprehensive educational content beyond the handouts typically shared. Additionally, as hospitals are often limited in how many CGT trials they can offer, adding a specialized CGT research team could potentially expand their capacity to offer more trials and treat more patients.

    This research will inform Vor Bio's communications approach for future clinical trials and how the Company can help support patients and partner institutions through the enrollment process. Vor Bio plans to continue this research to uncover additional learnings that may lead to further improvements in the patient experience and CGT clinical trial enrollment.

    The study coauthors include staff at NMDP (National Marrow Donor Program), MDS Foundation, Memorial Sloan Kettering Cancer Center, University Hospitals Cleveland Medical Center, Miami Cancer Institute, and Stanford Medicine.

    About Vor Bio

    Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "aim," "anticipate," "can," "continue," "could," "design," "enable," "expect," "initiate," "intend," "may," "on-track," "ongoing," "plan," "potential," "should," "target," "update," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, including potential improvements in relapse-free survival, the timing of initiation of clinical trials, the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts while maintaining healthy blood count levels and change the standard of care for patients with blood cancers, the safety profile of trem-cel plus Mylotarg, the potential design of a registrational trial for trem-cel and plans for regulatory submissions for trem-cel. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; uncertainties regarding regulatory approvals to conduct trials or to market products; the success of Vor Bio's in-house manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements and Vor Bio's ability to continue as a going concern. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

    Contact:

    Investors & Media

    Sarah Spencer

    +1 857-242-6076

    [email protected]



    Primary Logo

    Get the next $VOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VOR

    DatePrice TargetRatingAnalyst
    7/26/2022$18.00Outperform
    Wedbush
    4/27/2022$6.00Neutral
    Goldman
    12/17/2021$26.00Buy
    HC Wainwright & Co.
    12/3/2021$38.00Outperform
    Robert W. Baird
    12/3/2021$38.00Outperform
    Baird
    12/2/2021$30.00Outperform
    Oppenheimer
    10/19/2021$40.00Market Outperform
    JMP Securities
    More analyst ratings

    $VOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

      SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

      11/14/24 4:33:50 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

      SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

      2/14/24 4:17:24 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

      SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

      2/14/24 4:08:06 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Ang Robert covered exercise/tax liability with 2,361 shares, decreasing direct ownership by 0.26% to 911,318 units (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/7/25 4:05:57 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Sci Off & Head Tech Ops Chakraborty Tirtha covered exercise/tax liability with 876 shares, decreasing direct ownership by 0.40% to 217,416 units (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/7/25 4:05:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Choi Han Wook covered exercise/tax liability with 2,061 shares, decreasing direct ownership by 4% to 51,280 units (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/2/25 4:30:56 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      1/2/25 7:42:04 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

      CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund. Mr. Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. Currently the Managing Member of

      1/8/25 9:00:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

      CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. His deep expertise in structuring corporate partnerships and investments, managing complex transact

      9/30/24 7:00:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

      CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company's fully integrated business and advancing a broad pipeline of innovative medicines to address significant medical needs in oncology/hematology and allergy/inflammation. With over two decades of experience in

      5/2/24 4:01:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    SEC Filings

    See more
    • Vor Biopharma Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - Vor Biopharma Inc. (0001817229) (Filer)

      5/8/25 8:35:56 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFR14A filed by Vor Biopharma Inc.

      DEFR14A - Vor Biopharma Inc. (0001817229) (Filer)

      4/30/25 4:04:48 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Vor Biopharma Inc.

      8-K - Vor Biopharma Inc. (0001817229) (Filer)

      4/25/25 4:01:13 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Vor Biopharma with a new price target

      Wedbush initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $18.00

      7/26/22 8:25:46 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Vor Biopharma with a new price target

      Goldman initiated coverage of Vor Biopharma with a rating of Neutral and set a new price target of $6.00

      4/27/22 6:14:19 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Vor Biopharma with a new price target

      HC Wainwright & Co. initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $26.00

      12/17/21 6:23:13 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

      CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

      5/8/25 8:30:15 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Announces Annual Results for Year Ended December 31, 2024

      Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 20

      4/30/25 2:00:00 AM ET
      $PRTC
      $VOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

      VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025$55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.  "We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our cl

      3/20/25 4:05:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Financials

    Live finance-specific insights

    See more
    • Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

      CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

      5/8/25 8:30:15 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

      Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

      12/9/24 7:30:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

      Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic wind

      9/5/24 4:01:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care